Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Common Equity: 2013-2024

Historic Common Equity for Fortress Biotech (FBIO) over the last 12 years, with Dec 2024 value amounting to $22.7 million.

  • Fortress Biotech's Common Equity rose 611.74% to $65.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.2 million, marking a year-over-year increase of 611.74%. This contributed to the annual value of $22.7 million for FY2024, which is 0.86% up from last year.
  • Latest data reveals that Fortress Biotech reported Common Equity of $22.7 million as of FY2024, which was up 0.86% from $22.5 million recorded in FY2023.
  • In the past 5 years, Fortress Biotech's Common Equity registered a high of $225.9 million during FY2021, and its lowest value of $22.5 million during FY2023.
  • Moreover, its 3-year median value for Common Equity was $22.7 million (2024), whereas its average is $31.8 million.
  • In the last 5 years, Fortress Biotech's Common Equity soared by 171.60% in 2020 and then tumbled by 77.85% in 2022.
  • Yearly analysis of 5 years shows Fortress Biotech's Common Equity stood at $197.0 million in 2020, then grew by 14.66% to $225.9 million in 2021, then tumbled by 77.85% to $50.0 million in 2022, then plummeted by 54.93% to $22.5 million in 2023, then increased by 0.86% to $22.7 million in 2024.